Grace Therapeutics (GRCE) EBITDA (2019 - 2026)
Grace Therapeutics (GRCE) posted EBITDA of -$3.0 million for Q1 2026, down 22.91% sequentially from -$2.4 million in Q4 2025, and up 5.44% YoY from -$2.9 million in Q1 2025.
Grace Therapeutics (GRCE) EBITDA (2019 - 2026) Analysis & Trends
Grace Therapeutics has reported EBITDA for 8 years, with the latest figure at -$3.0 million in Q1 2026.
- Quarterly EBITDA rose 5.44% year-over-year to -$3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.1 million (up 33.59% YoY) and the FY2026 annual result came in at -$11.1 million, up 33.59% from the prior year.
- EBITDA eased to -$3.0 million in Q1 2026 per GRCE's latest filing, from -$2.4 million in the prior quarter.
- Over five years, EBITDA peaked at -$2.1 million in Q3 2023 and troughed at -$38.1 million in Q1 2023.
- A 5-year average of -$5.7 million and a median of -$3.7 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2024: EBITDA sank 764.71% in 2023, then soared 91.43% in 2024.
- Over 5 years, EBITDA stood at -$4.2 million in 2022, then climbed by 28.32% to -$3.0 million in 2023, then fell by 21.72% to -$3.7 million in 2024, then surged by 33.88% to -$2.4 million in 2025, then slipped by 22.91% to -$3.0 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$3.0 million, -$2.4 million, and -$2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Grace Therapeutics | 37.04 Mn | 37.04 Mn | - | -15.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.92 Mn |
| Mar 31, 2026 | -3.01 Mn |
| Dec 31, 2025 | -2.45 Mn |
| Sep 30, 2025 | -2.53 Mn |
| Jun 30, 2025 | -3.09 Mn |
| Mar 31, 2025 | -3.18 Mn |
| Dec 31, 2024 | -3.70 Mn |
| Sep 30, 2024 | -4.83 Mn |
| Jun 30, 2024 | -4.96 Mn |
| Mar 31, 2024 | -3.26 Mn |
| Dec 31, 2023 | -3.04 Mn |
| Sep 30, 2023 | -2.09 Mn |
| Jun 30, 2023 | -4.45 Mn |
| Mar 31, 2023 | -38.07 Mn |
| Dec 31, 2022 | -4.25 Mn |
| Sep 30, 2022 | -5.11 Mn |
| Jun 30, 2022 | -4.73 Mn |
| Mar 31, 2022 | -4.40 Mn |
| Dec 31, 2021 | -4.47 Mn |
| Sep 30, 2021 | -3.57 Mn |